Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma

References

• Festic E, Gajic O, Limper AH, et al. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128(2):573–579.
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med. 1995;155(11):1125–1128.
   PubMedGoogle Scholar
• Roembke F, Heinzow HS, Gosseling T, et al. Clinical outcome and predictors of survival in patients with Pneumocystis jirovecii pneumonia–results of a tertiary referral centre. Clin Respir J. 2014;8(1):86–92.
   PubMed Web of Science ®Google Scholar
• Obeid KM, Aguilar J, Szpunar S, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk. 2012;12(1):66–69.
   PubMed Web of Science ®Google Scholar
• Barreto JN, Ice LL, Thompson CA, et al. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. Am J Hematol. 2016;91(11):1113–1117.
   PubMed Web of Science ®Google Scholar
• Kamel S, O’Connor S, Lee N, et al. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010;51(5):797–801.
   PubMed Web of Science ®Google Scholar
• Tadmor T, McLaughlin P, Polliack A. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk Lymphoma. 2010;51(5):737–738.
   PubMed Web of Science ®Google Scholar
• Kim T, Choi SH, Kim SH, et al. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Ann Hematol. 2013;92(2):231–238.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–1059.
   PubMed Web of Science ®Google Scholar
• Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis. 2011;5(1):41–59.
   PubMedGoogle Scholar
• Arcenas RC, Uhl JR, Buckwalter SP, et al. A real-time polymerase chain reaction assay for detection of Pneumocystis from bronchoalveolar lavage fluid. Diagn Microbiol Infect Dis. 2006;54(3):169–175.
   PubMed Web of Science ®Google Scholar
• Caliendo AM, Hewitt PL, Allega JM, et al. Performance of a PCR assay for detection of Pneumocystis carinii from respiratory specimens. J Clin Microbiol. 1998;36(4):979–982.
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Belaz S, Revest M, et al. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study. J Clin Microbiol. 2014;52(9):3370–3376.
   PubMed Web of Science ®Google Scholar
• Wilson JW, Limper AH, Grys TE, et al. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis. 2011;69(2):145–152.
   PubMed Web of Science ®Google Scholar
• Fossa A, Fiskvik IH, Kolstad A, et al. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Ann Oncol. 2012;23(5):1254–1259.
   PubMed Web of Science ®Google Scholar
• Kalin M, Kristinsson SY, Cherif H, et al. Fatal Pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. Ann Hematol. 2010;89(5):523–525.
   PubMed Web of Science ®Google Scholar
• Longo DL, DeVita VT, Jr., Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991;9(1):25–38.
   PubMed Web of Science ®Google Scholar
• Porzig KJ, Portlock CS, Robertson A, et al. Treatment of advanced Hodgkin’s disease with B-CAVE following MOPP failure. Cancer. 1978;41(5):1670–1675.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Seo K, Yoshino Y, et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother. 2019;25(5):351–354.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–715.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii70–75.
   PubMed Web of Science ®Google Scholar
• Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev. 2012;25(2):297–317.
   PubMed Web of Science ®Google Scholar
• Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010;5(1):43–65.
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Slavin MA, Seymour JF, et al. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol. 2013;91(2):157–163.
   PubMed Web of Science ®Google Scholar
• Liebling M, Rubio E, Ie S. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?. Expert Rev Respir Med. 2015;9(2):171–181.
   PubMed Web of Science ®Google Scholar
• Mathas S, Hartmann S, Kuppers R. Hodgkin lymphoma: pathology and biology. Semin Hematol. 2016;53(3):139–147.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Stanelle J, Hansmann ML, et al. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151–174.
   PubMed Web of Science ®Google Scholar
• Fukutani Y, Chigusa Y, Kondoh E, et al. Pneumocystis pneumonia in non-HIV pregnant women receiving chemotherapy for malignant lymphoma: two case reports. Case Rep Obstet Gynecol. 2017;2017:1073146
   PubMedGoogle Scholar
• Kofteridis DP, Valachis A, Velegraki M, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother. 2014;20(7):412–416.
   PubMed Web of Science ®Google Scholar
• Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127:1242 e1211.
   Web of Science ®Google Scholar
• Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350–1363.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179–184.
   PubMed Web of Science ®Google Scholar
• Madu A, Ocheni S, Ibegbulam O, et al. Pattern of CD4 T-lymphocyte values in cancer patients on cytotoxic therapy. Ann Med Health Sci Res. 2013;3(4):498–503.
   PubMedGoogle Scholar
• Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297(26):1419–1426.
   PubMed Web of Science ®Google Scholar
• Muto T, Takeuchi M, Kawaguchi T, et al. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1573–1575.
   PubMed Web of Science ®Google Scholar
• Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29(6):1467–1471.
   PubMed Web of Science ®Google Scholar
• Vasconcelles MJ, Bernardo MV, King C, et al. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6(1):35–43.
   PubMed Web of Science ®Google Scholar
• Caselli D, Petris MG, Rondelli R, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr. 2014;164(2):389–92.e1. 392 e381.
   PubMed Web of Science ®Google Scholar
• Golden JA, Katz MH, Chernoff DN, et al. A randomized comparison of once-monthly or twice-monthly high-dose aerosolized pentamidine prophylaxis. Chest. 1993;104(3):743–750.
   PubMed Web of Science ®Google Scholar
• Szklo M, Nieto FJ. Epidemiology: beyond the basics. Sudbury (MA): Jones and Bartlett Publishers; 2007. xiii, 489p.
   Google Scholar
• Arfe A, Corrao G. Tutorial: strategies addressing detection bias were reviewed and implemented for investigating the statins-diabetes association. J Clin Epidemiol. 2015;68(5):480–488.
   PubMed Web of Science ®Google Scholar
• Blum RH, Carter SK, Agre K. A clinical review of bleomycin–a new antineoplastic agent. Cancer. 1973;31(4):903–914.
   PubMed Web of Science ®Google Scholar
• Willson JK. Pulmonary toxicity of antineoplastic drugs. Cancer Treat Rep. 1978;62(12):2003–2008.
   PubMedGoogle Scholar
• Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74(7):730–734.
   PubMed Web of Science ®Google Scholar
• Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf. 2000;22(3):227–236.
   PubMed Web of Science ®Google Scholar
• Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004;24(3):477–490, vii.
   PubMed Web of Science ®Google Scholar
• Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. J Allergy Clin Immunol Pract. 2019;7(7):2116–2123.
   PubMed Web of Science ®Google Scholar
• Dibbern DA, Jr., Montanaro A. Allergies to sulfonamide antibiotics and sulfur-containing drugs. Ann Allergy Asthma Immunol. 2008;100(2):91–100. quiz 100-103, 111.
   PubMed Web of Science ®Google Scholar
• Imrie KR, Prince HM, Couture F, et al. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant. 1995;15(2):267–270.
   PubMed Web of Science ®Google Scholar